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ABSTRACT 
The enzymopathic hypothesis of the aetiology of 
coeliac disease (CD) is still relevant as a mechanism 
operating in this disease and a form of therapy based on 
the use of enzymes which are deficient in CD is 
currently being evaluated. This approach is based on 
the premise that if gluten and other offending proteins 
are completely digested in the small intestinal mucosa 
with the aid of supplementary enzymes, an adverse 
response will not occur. This is comparable to the 
situation in those who do not suffer from this disease, 
where there is neither direct toxic action nOf an 
abnormal immunological response to cause damage to 
-the mucosa. 
Enzyme therapy offers a way of safeguarding the 
integrityof the small intestineforpati ents against traces 
of gluten ingested whilst attempting to maintain a strict 
gluten-free diet. Furthermore, in the future, the 
efficiency of this approach may develop to the point 
where minor indulgence in some favourite 'foods and 
beverages, maybe possible. 
KEYWORDS: coeliac disease, enzyme therapy, 
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INTRODUCTION 
A great deal of evidence has been now obtained 
to support the enzymopathic hypothesis of CD. In 
recent years, considerable efforthas gone into a better 
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understanding of the mechanisms of pathogenesis, but 
has mostly overlooked the basic cause or aetiology of 
the disease. There is therefore a need to separate 
mechanisms of aetiology from those which are 
importantin pathogenesis. 
When this is done, it becomes likely that the damage to 
tissue seen in CD is caused by increased concentrations 
of undigested pep tides derived from wheat, rye and 
barley resulting from their defective digestion in the 
small bowel with subsequent initiation of 
immunologicaly mediated reactions. There is also the 
likelihood of direct toxicity resulting from these higher 
concentrations of peptides. 
Background 
The background research carried out in orderto define 
the present understanding of the value of enzyme 
therapy has been achieved by: 
1. The fractionation of gluten into 
components which differ in their toxic 
properties. 
2. In vitro assays oftoxicityforfractions. 
3. Chemical analysis and differentiation of 
fractions of gliadin digests. 
4. Confirmation of chemical composition and 
structure by the use of synthetic pep tides. 
5. Confirmation of toxicity by in vivo 
methods. 
6. Further studies on the mechanism of 
toxicity. 
7. Studies of immunological mechanisms of 
pathogenesis. 
8. Clinical trials of therapeutic products. 
Each of these points will now be discussed. 
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1. The fractionationofgluten. 
The separation of the components of wheat proteins has 
long been of importance. Since the gliadin fraction has 
emerged as a source of the toxic substances in wheat 
(1) much research has been done to determine the most 
toxic proteins present (2) and this has also extended to 
peptic-tryptb-pancreatinic (PTe) digests of gliadin 
(3,4). These digests are ideal to work with as they are 
water soluble and of molecular weight about 1500 
Daltons, meaning that peptides are tested which would 
be of similar size to those presented to the small 
intestine. 
The gliadin fraction of wheat is readily obtained by 
extraction with 70% (v/v) ethanol, and although the 
insolUble higher molecular proteins, the glutenins, 
contribute to toxicity, the gliadin fraction, generally 
known as the prolaminfraction,is regarded as being the 
more toxic to coeliacs (5). This fraction also contains 
the toxic proteins of rye, barley and oats. The gliadins 
can be separated into electrophoreticfractions a-, j3-, r-
and 00- gliadins and ion-exchange procedures can be 
employed to separate fractions corresponding to these 
gliadins. However, the PTC digests present the best 
opportunity for differentiation of toxicity, if we base 
this on specific amino acid sequences in small peptides. 
The fractionation of PTC gliadin digest was achieved 
by chromatograpty on SP Sephadex (Pharmacia, 
Uppsala, Sweden) by the use of phosphate buffers and 
increasing pH (4). 
2. I n vitro assays of toxicity 
One of the earliest useful assays of activity showed that 
intestinal mucosa from patients with active coeliac 
disease recovered histologically after 24 hours in 
culture in the absence of gluten but remained damaged 
in the presence of gliadin (6). 
This proved to be a useful method for evaluating the 
toxicity of gliadin fractions. It was shown that one 
fraction of the PTe gliadin digest (fraction 9) prevented 
recovery of the mucosa compared to the other 9 
fractions of the digest, as shown by electron 
microscopy(7). 
This was supported by another much simpler assay 
based on disruption of rat-liver lysosomes, where, 
again, fraction9 was the most active(8). 
Fraction 9 and one of its sub-fractions(9-2) were shown 
to retain activity to developing foetal rat intestine 
and cultured atrophic celiac mucosa after preliminary 
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digestion by intestinal mucosa from coeliac patients in 
remission (9). Digestion with normal mucosa abolished 
this activity, lending strong support to a mucosal 
deficiency in the coel iac patients. 
3. Chemical analysis and differentiationof fractions 
of gliadin digests. 
Amino acid analysis of the various fractions revealed 
that initial fractions were rich in acidic N-pyrrolidone 
carboxylyl peptides, whilst the latter ones such as 
fraction 9 were types rich in proline, glutamine, 
togetherwith serine, tyrosineand leucine and were thus 
more neutral in nature. The most importantfindingwas 
that fraction 9 was the least completely digested by 
histologicalt:i normal remission celiac mucosa of all the 
fractions. All fractions were equally well digested by 
mucosa from normal individuals. The undigested 
peptides were readily seen after chlorination and 
staining with starch (9). 
Pursuing this workfurther,it was shown that there were 
peptide residues from fraction 9 after digestion with 
mucosa fromsome first degree relatives of the coeliacs 
who did not have coeliac disease according to 
histological criteria( 1 0). 
These experiments pointed to a peptidase deficiency in 
coeliac disease and a partial deficiency in the first 
deg ree relatives of those with this disease. 
4. Confirmation of chemical structure by the use of 
synthetic peptides. 
A huge breakthrough occurred with the elucidation of 
the amino acid sequence of A-gliadin, representative of 
the structure of a-gliadins (11).Based on this structure, 
de Ritis et al. (12) found that there were key sequences 
of four amino acids associated with toxic fractions 
prepared from A-gliadin, these being QQQP and 
PSQQ. 
It was importantto determine the amino acid sequences 
of peptides in fractions of native gliadin. Fraction 9 was 
subjected to reverse-phase HPLC, the resulting 
fractions analysed foramina acid composition and the 
major ones rechromatographe! and then sequenced 
(13). The most abundant peptide corresponded to 
residues 75-86 of A-gliadin (RPQQPYPQPQPQ). 
Fraction 9 and this peptide, prepared synthetically, 
stimulated the production of r-interferon in peripheral 
blood from coeliac patients in remission to a greater 
degree than in blood from normals (14). It was thought 
that the key sequence in this peptidecouldbeafour 
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amino acid motiflike QQPY or PYPQ. 
The toxicity of fraction 9 and synthetic peptides 
correspondingto sub-fractionsof fraction 9, were tested 
in the foetal chick assay of Mothes et al. (15). Fraction 
9 was very active in this assay whilstpeptide 75-86was 
active, but less so than fraction 9 (16). The reason for 
this was soon discovered to be due to the presence of 
another peptide containing serine from near the N-
terminus of A-gliadin, corresponding to residues 9-19 
(QPQNPSQQQPQ).This peptide contains two of the 
de Ritis key motifs, PSQQ and QQQP (overlapping) 
and was very active in the foetal Chick assay. Using the 
technique of amino acid deletions, it was found that the 
most active peptide within this sequence was peptide 
11-19 (17), appreciably more active than 8-19, reported 
by Kocna et al. using the same assay (18).Surprisingly, 
this peptice did not cause release of 'Y-interferon,as did 
the tyrosine-contairing peptide 75-86 (14). This 
suggested that the mechanism of activity wcy; different 
for the serine containing peptide and it is generally 
considered that the foetal chick assay measures 
predominantly, cytotoxicity. Direct cytotoxicity of 
gliadin components has been questioned and also 
demonstrated with the A-gliadin peptide 31-43, which 
damages enterocytes but is not able to activate coeliac 
intestinal CD4+T clones (19), required for a 
proliferation of the immune response and tissue 
damage. Other peptides in this area such as peptide 31-
49 (LGQQQPFPPQQPYPQPQPF) have not only the 
QQQP motif,but the QQPY motif, and has been shown 
to be toxicin vivo(20). 
Near the C-terminus, peptides 208-219 (18) and 206-
217 (21) have been shown to be toxic. It should be 
noted that both these pepUdes contain the PSQQ motif. 
5. Confirmationoftoxicityby in vivornethods 
Early studies of toxicity of gliadin proteins, showed 
that all major electrophoretic fractions had 
demonstrable effects on the small intestinal mucosa. 
These studies comprised direct instillation of fractions 
into the proximal small intestine, follOWed by biopsies 
taken at measured intervals (22). Fraction 9 was first 
tested using the xylose tolerance test on teenage 
children who gave positive results to a PTC digest of 
gliadin. Vv11en these children were fed all the fractions 
except fraction 9, no reduction in urinary xylose was 
observed, but after fraction 9 was fed there was about a 
35% reduction on average (23). 
Other tests in which the fractions of gliadin from CM 
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Sephadex (Pharmacia, Uppsala, Sweden) were each 
digested with pepsin, trypsin and pancreatin and 
fractionated to produce fraction 9-type sub-fractions 
showed that fractions corresponding to a-, p- and y-
gliadins were incompletely digested by remission 
coeliac mucosa, thus connecting the above in vivo 
studies (22) with the peptide deficiency theory of 
toxicity (9). 
As previously mentioned, the preparation of larger 
amounts of synthetic peptides having structures based 
on sections of the A-gliadin molecule has led to 
confirmation of the activity in the regions 31-49 (20) 
and 206-217 (21). 
Further studies with all three coel iac-toxic cereals are 
required to confirm that specific peptides in each are 
responsible. At this stage, such studies using protein 
data bases show that the extended motifs QQPYP, 
PQQPY and QQQPFP are each present in wheat, rye 
and barley, but not in the non-toxic cereals rice and 
corn (24). The latter motif is present in oats, which 
remains under scrutiny for toxicity. 
6. Furtherstudles on themechanism of toxiCity 
Most of the studies undertaken by other groups 
concentrate on the pathogenesis of the disease and tend 
to neglect the reason why the peptides are present in 
such significant concentrations. Certainly, the 
presentation of gliadin peptides to T-cells can occur in 
the proximal small intestine of normal individuals as 
well as in coeliacs, but in normals, the enzymes present 
would quickly lower the concentrations of toxic 
pep tides, whereas this does not appear to happen with 
remission coeliacs. Evidence for this comes from 
mucosal digestion studies of synthetic toxic peptides 
(25,26). In both cases whereserine-containirg peptides 
(8-19; 11-19) and tyrosine-contairing peptides (75-85; 
75-86) were used, residues of peptides such as octa-
peptides were obtained from remission coeliac 
digestion in much higher quantities than from normal 
digestion. Wlat is more, the serine and tyrosine in each 
peptide were retained in the undigested residues, 
suggesting that the active motifs in the peptides (PSQ Q, 
QQPY respectively) remained undigested, supporting 
the importance of these motifs to toxicity. The residual 
peptides corresponded mainly to NPSQQQPQ and 
QQPYPQPQin each case. 
An explanation of the different types of toxicity present 
in the serine-containirg and tyrosine-contairing 
peptideshas been provideciJsing molecularmodel ing(27). 
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Serine.-containirg peptides like peptide 11-19 are 
stabilized by hydrogen bonding into a helical structure 
which has been shown to be importantin cytotoxicity 
(28). the prominent type of activity measured in the 
chick assay. On the other hand, tyrosine-contairing 
peptides like 75-86 appear to be random coil types, 
with much ·Iess hydrogen bonding, are more 
immunogenic and they can bring about cytokine 
production and othersequella through interaction with 
T -cells. VIhlat is common to both types of peptides is 
their inability to be completely digested by remission 
coeliac mucosa, thus providing the trigger for tissue 
damage. 
7. Studies of immunological mechanisms of 
pathogenesis 
CD is associated mainly with the HLA class II 
extended haplotypes DR3-DQ2 or DR517-DQ2. The 
DQ2 molecule is an alJ3 heterodimer and plays an 
important role in the immune response. Most patients 
with CD but also 20% of the general population carry 
the risk alleles encoding for DQ2 (29). Hence, other 
susceptibility genes of quite different function are 
possible and it could tum out that those relating to 
defective peptidase synthesis may be discovered. 
The immunological data suggest that pathogenesis of 
CD results from the way in which gliadin peptides are 
presented to T-cells. The peptidesare presented by CD-
specific HLA-DQ2-positive antigen-presentng cells 
and reactions which damage the lamina propria are 
potentiated by tissue transglutaminase(30). HLA-DQB-
positive antigen-presen1ng cells are also involved in 
some patients. 
Obviously, in the case of immune mechanisms which 
are involved in the pathologyof CD, the presentationof 
antigenic gliadin peptides by the HLA-DQ2 and HLA-
DQB coeliac-specific positive antigen-presenthg cells 
must be considered as a primary event in pathogenesis 
(31 ).It appears that increases in the affinityof peptides 
for these molecules can be induced by selective 
deamidation by transglutamirase (30), leading to 
epitopes which can be recognized by T -cells when 
presented to DQ2 molecules. Molberg et al. (31) 
provided evidence for tTG in CD as having a role in 
selective[y deamidating gliadin peptides that are 
recognized by T -cells in the small intestine. However, 
this is not to say that high [evels of transglutanirase 
could be a basic cause of CD, but rather that they would 
amplify the immunologicalresponse. 
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It is of importance to note that after selective 
deamidation of the immunoreactive peptide of 
Anderson et a!. (32), the tyrosine-contairing motif 
PVPQ is still present, which has been associated with 
the toxicity of several peptides from A-gliadin such as 
31-49 (20) and 75-86 (16). 
Tyrosine-containing peptide residues are common to 
the experiments involving mucosal digestion such as 
QQPYPQPQ (peptide 77-84 of A-gliadin). 
Immunoreactive peptides such as peptide 57-73 (32) 
and peptide 45-60 from A-gliadin (33) also contain 
tyrosine and are often present as 4-mer motifs such as 
QQ PY orQPYP. Peptide31-49 (20), shown to be toxic 
in vivoto patients with CD, has both these motifs, but 
also has QQQP, one of two 4-mer motifs suggested by 
de Ritis et al. (12), the other being PSQQ, commonly 
found associated with in vitro activity and shown to be 
toxic in vivo as peptide 206-217(21). 
The disruption of this PSQQ motif associated with 
toxicity is not achieved by remission coeliac mucosa 
(25) but would be achieved by prolyl endopeptidases, 
which attack proline residues on their C- terminal side. 
The same applies to peptides containing the 
QQPY/QPYP motif, thus reinforcing the notion of a 
specific peptidasedeficiencyof this typein CD (26). 
8. Clinical trials of therapeuticproducts 
The discovery of an enzyme deficiency in coeliac 
disease has opened the way for therapy using enzyme 
supplementation. A genetic defect is likely in CD 
which prevents the biosynthesis of enzymes,especially 
peptidases. The results of mucosal digestion studies 
suggest that endopeptidases which are needed to split 
the key motifs of toxic fractions of gliadin are required 
in coeliac mucosa before complete digestion can occur. 
If such a productcou[d be introduced into the proximal 
small intestine intact i.e. avoiding digestion by pepsin, 
trypsin etc., it could complete the digestion of the 
gliadin peptides to amino acids and very small peptides 
which are incapable of harming intestinal cells and 
tissue. After all, an amino acid mixture corresponding 
to the wheat proteins is not toxic to coeliac patients. 
Such a product has been developed by Cornell and 
Stelmasiak (34) and has undergone successful clinical 
trials (35). It is in the form of an enterically coated 
capsule containing an animal intestinal extract. Such 
extracts can be prepared from pig, cow or sheep 
intestine,which is in keeping with the findiogthat higher 
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animals do not suffer from CD. These animals have 
been eating cereal crops for much longer periods of 
time than humans and have thus acquired the necessary 
enzymes. 
Endopeptidases have been found in tile brush borderof 
human enterocytes (36) and Hausch et al. (37) have 
found that a bacterial prolyl endopeptidase reduces the 
antigenicity of a gliadin peptide. These enzymes 
(EC3.42126) cleave peptide bonds on the C-terminal 
side of proline residues (38) and would thus cleave the 
motifs of both the active serine-containirg and 
tyrosine-contairing peptides (PSQQ and QQPY/QPYP 
respectively). 
Work is proceeding to identify the enzymes in the cow 
and pig responsible for detoxifying the gliadin and has 
shown that the form of enzymein both animals has a 
molecular weight between 170 and 200 kD. This 
fraction from gel permeation chromatography of the 
intestinal extract is by far tile most active forabolishing 
the activity of PTC gliadin digests towards rat liver 
Iysosomes. These tests need to be extended to toxic 
fractions from rye and barley and even oats. In A-
gliadin, the extended motifs containing tyrosine which 
are commonto wheat, rye and barley occur at positions 
33-38,40-44,76-80 and 77-81 (as in toxic peptides 31-
49 and 75-86) and this interesting finding would 
support such initiatives. 
Enzyme therapy is a safeguard against the serious 
effects of long-termingestion of small amountsof these 
cereals. At present the product will counteract only 
small amounts of gluten, but in the future, a more 
potent product i.e. one with higher specific activity, 
will be manufactured ,thus allowing more liberty in the 
choice of food items forthe nominal gluten-freediet. 
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